Novartis will appeal Entresto patent setback

Novartis has suffered a defeat in its legal defence of chronic heart failure therapy Entresto, which accounted for around 11% of its revenues last year, but has vowed to t

FDA okays Viatris' insulin drug as first 'interchangeable' b...

Generic drugmaker Viatris has become the first company to secure FDA approval for a biosimilar product that is considered completely interchangeable with the reference product – namely Sano

FTC clears Mylan merger with Pfizer’s Upjohn – with conditio...

Mylan’s $12 billion takeover of Pfizer’s Upjohn unit has been cleared by the US authorities, but on the condition that the two companies divest various generic drug products.

Coronavirus pandemic delay Mylan and Pfizer's generics merge...

Mylan’s merger with Pfizer’s off-patent drug business has been delayed until later this year because of the coronavirus pandemic.

COVID-19 could disrupt supplies of cheap generics, analysts ...

An extended COVID-19 coronavirus outbreak could impact on supplies of generic drugs that many health systems rely on to keep costs as low as possible, according to a new report from ratings

Biogen claims victory in patent dispute with Mylan over MS d...